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1. Introduction
Ischemic heart disease is a clinical syndrome resulting from myocardial ischemia and is
characterized by an imbalance between the supply and demand of myocardial blood flow
and myocardial oxygen metabolism. It is currently one of the major diseases that endanger
human health. Early and effective reconstruction of ischemic myocardial blood perfusion is
the fundamental measure taken to prevent the development of ischemic myocardial injury,
reduce myocardial infarct size, and improve the clinical prognosis. However, several studies
have discovered that in some cases, reperfusion of ischemic cells could cause further injury
in the form of ischemia/reperfusion injury. The clinical manifestations of myocardial ische‐
mia-reperfusion injury include arrhythmia, myocardial stunning, and no-reflow. Although
lethal reperfusion injury in clinical practice is more difficult to identify, it is the most serious
consequence of ischemia/reperfusion injury and is also the main reason preventing the is‐
chemic myocardium recovery from effective reperfusion therapy. Therefore, studies on the
modes of myocardial cell death after ischemia/reperfusion are of great significance. Previous
studies suggested that myocardial cell death following myocardial ischemia/reperfusion in‐
jury were mainly necrosis and apoptosis. Apoptosis receives more attention due to its death
program. However, in recent years, a number of studies have suggested that, another proce‐
dural manner of death---autophagy, type II programmed cell death, also plays a critical role
in ischemia/reperfusion injury. The study of this death pathway may provide a new effec‐
tive way to block myocardial ischemia/reperfusion injury. Therefore, in this chapter, the
roles and possible mechanisms of autophagy in myocardial ischemia/reperfusion injury will
be reviewed.
© 2013 Zhang et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Definition, formation and classification of autophagy
In 1962, Ashford and Porter discovered the ‘self-eating’ phenomenon in liver cells using an
electron microscope [1]. After that, this process was named autophagy by Duve, a Belgian
cellular biologist and chemist [2].
Autophagy is the transportation and degradation of damaged, denatured or aged proteins.
It is a common cellular physiological process which can maintain cell homeostasis. Autopha‐
gy is an evolutionary conserved pathway of self-digestion that occurs in various eukaryotic
organisms from yeast to mammals [3]. It is also a cellular defense mechanism in many
pathological processes. The autophagy process time is relatively short (T1/2 for 8 mins), it
illustrates that autophagy is an effective response to environmental changes for cells, and it
plays a pivotal role in metabolism: (1) Since autophagy is an adaptive response to exoge‐
nous stimuli (including nutritional deficiencies, the cell density load, hypoxia, oxidative
stress, infection, etc.), and its products of degradation, such as amino acids, nucleotides, and
free fatty acids, can participate in the material and energy cycle; (2) As a housekeeper mech‐
anism for cells to maintain a steady state, autophagy can adjust the renovation of long-lived
proteins, peroxisomes, mitochondria and endoplasmic reticulum; (3) Autophagy is involved
in tissue-specific integration; (4) Autophagy can act as a defense mechanism to remove the
damaged cytoplasm and metabolites, and the reconstruction on the subcellular level can
protect the affected cells. Meanwhile, as a cell death procedure, autophagy can induce cell
initiative death [4].
Although autophagy and autophagy-related processes are dynamic, they can be broken
down into several discrete steps. There are four steps in autophagy: induction, formation of
autophagosomes, formation of autolysosomes and degradation of the content. Autophagy
serves as a response to stress such as nutrient limitation, and this is one of its primary roles
in unicellular organisms such as yeast. Then, portions of cytoplasm are first isolated (seques‐
tered) within a double membrane enclosed vacuole called an autophagosome. In studies on
yeast, the isolation membrane has been shown to develop from a small vesicle that later
transforms into a cup-like structure surrounding the material to be degraded [5]. The forma‐
tion of an autophagosome (sequestration) is complete when the edges of the ‘cup’ merge. It
has been found that the proteins forming the isolation membrane in yeast are unique, differ‐
ent from those in other cellular compartments, which suggests a de novo formation of this
membrane [6]. It is still discussed whether the isolation membrane also forms de novo in
higher organisms, including mammals, or if it originates from another organelle, such as en‐
doplasmic reticulum, lysosome or Golgi complex. The sequestration membrane that later
gives rise to the autophagosome has been termed phagophore or pre-autophagosome [7]. In
yeast and mammalian cells, autophagy occurs at a basal level. The general diameter of auto‐
phagosomes is 300-900 nm, and the average level is 500 nm. Since the beginning of the for‐
mation of the autophagosomes, cytoplasm and nucleoplasm become darker, but the nucleus
structure has no noticeable changes. Mitochondria and endoplasmic reticulum swell, Gorky
body expands, and then the membrane-specialized structures such as microvilli disappear,
membrane foamed and retracted. At the later stages of autophagy, the volume and number
Ischemic Heart Disease144
of autophagosomes filled with myelin or liquid increase, and then some gray ingredients
and a small number of condensated nuclear materials will exist. These features can be used
as morphological indicators during inspection.
Depending on the different ways cellular material is transported to lysosomes, there are
three types of autophagy: microautophagy, macroautophagy, chaperone-mediated autopha‐
gy (CMA). Macroautophagy is commonly referred to as autophagy, and the cytoplasm is
wrapped by the dropped bilayers from the non-ribosomal region of endoplasmic reticulum,
the Golgi apparatus and other bilayers. In microautophagy, it also goes through the same
process of wrapping, but the substrate is engulfed by inward invagination of the lysosomal
membrane. In the process of CMA, intracytoplasmic proteins are bound to the molecular
chaperone, then transported to the lysosome cavity, and digested by the lysosomal enzyme.
CMA sequester proteins that expose a KFERQ-like pentapeptide which are mediated by
heat shock cognate 70 (HSC70) and its co-chaperones. Lysosomal-associated membrane pro‐
tein 2 (LAMP-2A) acts as a receptor on the lysosome and mediates the degradation of un‐
folded proteins. Macroautophagy is the major regulated cellular pathway for degrading
long-lived proteins and the only known pathway for degrading cytoplasmic organelles (Fig‐
ure 1). Therefore, this chapter focuses on macroautophagy.
3. Signaling regulation of autophagy
Autophagy is highly conservative during the evolution process. Homologous gene partici‐
pation in autophagy not only be found in yeasts and Drosophila melanogaster but also in
vertebrates and humans. In order to unify the standard, Klionsky, in 2003, named these ho‐
mologous genes as autophagy-related genes (Atg) to stand for autophagy genes and the cor‐
responding proteins [8]. So far, scientists have already found more than 30 Atgs and most of
their homologous analogues. In addition, the Atg protein can be divided into five groups:
Atg1 protein kinase complex, Atg9, the class III phosphatidylinositol 3-kinase (PI3K)-Be‐
clin1complex, Atg12 conjugation system and Atg8 conjugation system. Atg1 protein kinase
complex is essential for the induction of autophagy. There are two mammalian homologs of
Atg1 that appear to function in autophagy, the Unc-51-like kinase 1 (ULK1) and -2 (ULK2),
which is the mammalian homologues of serine/threonine protein kinase Atg1, existing in the
form of ULK1-mammalian Atg13 (mAtg13) -focal adhesion kinase family interacting protein
of 200 kDa (FIP200) -Atg10 complex [9]. Under nutritional deficiency conditions, ULK1 is ac‐
tivated and then phosphorylates mAtg13, FIP200 and itself to initiate autophagy. Regarding
the substrates of the Atg1 kinase during autophagy, it is suggested that mAtg13 and FIP200
are phosphorylated by ULKs, and ULKs also undergo autophosphorylation, which is con‐
ducive to a conformational change and autophagy induction. Mammalian target of rapam‐
mycin (mTOR) can phosphorylate and inactivate ULKs and Atg13 under nutrient-rich
conditions. Upon mTOR inhibition by starvation or rapamycin, ULK1 and ULK2 are activat‐
ed and phosphorylate Atg13 and FIP200, which are essential for autophagy activity. Recent
studies have suggested that Atg13 may be phosphorylated by TOR or Atg1/ULKs on differ‐
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ent residues [10]. It is likely that phosphorylation of Atg13 is dependent to a greater extent
on TOR in yeast, but on Atg1 in Drosophila.
Figure 1. Different Types of Autophagy (Cite from < Mizushima N, Komatsu M. Cell 2011;147(4) 728-741>).
The conjugation of Atg12 and Atg8 is essential for the formation of autophagosomes. Atg12
was the first ubiquitin-like Atg protein to be identified, which can be activated by Atg7 and
Atg10. Then it is conjugated to Atg5 and promotes the formation of the autophagy precursor
[11]. The amino-acid sequence of Atg12 ends with a glycine residue and there is no protease
involved in Atg12 conjugation. Analogous to ubiquitination, there is an E1-like enzyme,
Atg7, and Atg12 is activated by forming a thioester bond between the C-terminal Gly 186 of
Atg12 and the Cys 507 of Atg7. After activation, Atg12 is transferred to Atg10, which is an
E2 enzyme, and is eventually conjugated to the target protein Atg5 at Lys 149 through an
isopeptide bond. There is no typical E3 enzyme involved in Atg12-Atg5 conjugation. Atg5
interacts further with a small coiled-coil protein, Atg16, and Atg12-Atg5-Atg16 forms a mul‐
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timeric complex through the homo-oligomerization of Atg16. The ubiquitin-like (Ubl) pro‐
tein Atg8 is attached to phosphatidylethanolamine (PE). The C-terminal Arg 117 residue of
Atg8 is initially proteolytically removed by a cysteine protease, Atg4, to expose Gly 116.
This exposed glycine forms a thioester bond with Cys 507 of Atg7, which is also the site that
participates in the Atg12-Atg5 conjugation. This feature differentiates Atg7 from most other
E1 enzymes, which activate single Ubl proteins. Activated Atg8 is then transferred to the E2-
like enzyme Atg3, also through a thioester bond. In the final step of Atg8 lipidation, Gly 116
of Atg8 is conjugated to PE through an amide bond; Atg8-PE exists in a tightly membrane-
associated form. Microtubule-associated protein l light chain 3 (LC3) is the mammalian ho‐
mologues of Atg8. LC3 is activated by Atg7, transferred to Atg3, and conjugated to
phosphatidylethanolamine (PE) on the surface of autophagic vacuoles membranes to pro‐
mote the forming of autophagosomes [12].
Recently, the PI3K-Becline 1 complex and Atg9 have been shown to be the essential compo‐
nents involved in autophagy signaling and the membrane transportation of autophagic va‐
cuoles. This autophagy-specific class III-PI3K-Becline 1 complex appears to be essential to
recruit the Atg12-Atg5 conjugation to the pre-autophagosomal structure. Atg12-Atg5 conju‐
gation is then required for the elongation of the isolation membrane and for the proper lo‐
calization of conjugated LC3/Atg8 [13]. Atg9 is required for autophagy in both yeast and
mammalian cells and has been speculated to be involved in delivery of membrane lipids to
form autophagosomes. In mammalian cells, mAtg9 traffics between the trans-Golgi net‐
work, endosomes and newly formed autophagosomes [14].
Cells regulate autophagy through a set of precise signaling pathways including integrating
nutriment, growth factors, hormones, stress and intracellular energy information. A key reg‐
ulator point of autophagy in mammals is kinase mTOR. The kinase TOR is a major evolutio‐
narily conserved sensor in the autophagy signaling pathway in eukaryotes, but it also
regulates many other aspects of cell function, including transcription, translation, and cell
size and cytoskeletal organization. In mammals, mTOR can be included in two different
complexes, mTORC1 and mTORC2. Although these two TOR complexes share common
components, they display distinct cellular functions and phosphorylate different down‐
stream substrates. The activity of mTORC1 is regulated via the integration of many signals,
including growth factors, insulin, nutrients, energy availability, and cell stressors such as
hypoxia, osmotic stress, reactive oxygen species (ROS) and viral infection. mTORC1 is the
only known target of the drug rapamycin and is required for signaling to ribosomal S6 kin‐
ases (S6K) and eIF4E-binding proteins (4EBP1 and 4EBP2). mTORC1 has recently been
shown to consist of four proteins: mTOR, mLST8 (also known as GbL), proline-rich PKB/Akt
substrate 40-kDa (PRAS40), and raptor (regulatory associated protein of mTOR); and it
plays a major role in controlling translation and cell growth in response to nutrients. The
adaptor protein is common to both mTOR complexes. Raptor binds mTOR, S6K and
4EBP1/2 and facilitates mTOR phosphorylation of these molecules; but whether raptor en‐
hances or represses mTOR kinase activity remains unclear [15]. Unlike mTORC1, mTORC2
has some functions that cannot be inhibited by rapamycin, including the control of actin cy‐
toskeleton dynamics. The mTORC2 complex consists of mTOR, mLST8, mammalian stress-
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activated protein kinase-interacting protein 1 (mSin1), and rapamycin-insensitive
companion of mTOR (rictor). Recent studies indicate that when eutrophy, mTOR activates
the PI3K-I/ protein kinase B (PKB) signaling pathway, it leads multiple serine sites to phos‐
phorylation and then reduces the affinity of Atg13 and Atg1. Since Atg1-Atg13 compounds
decreased, Atg9 cannot be transferred to the autophagosome formation sites and autophagy
was inhibited.
AMP-activated protein kinase (AMPK) was initially identified as a serine/threonine kinase
that negatively regulates several key enzymes of the lipid anabolism. Meanwhile, AMPK is
regarded as the major energy-sensing kinase that activates a whole variety of catabolic proc‐
esses in multicellular organisms such as glucose uptake and metabolism, while simultane‐
ously inhibiting several anabolic pathways, such as lipid, protein, and carbohydrate
biosynthesis. Activated AMPK can inhibit mTOR by interfering with the activity of GTPase
Rheb and with protein synthesis, degrade the phosphorylation of ULK1 and promote disin‐
tegration of ULK1 from the mTOR compounds. In starved cells, when the AMP/ATP ratio
increases; the binding of AMP to AMPK promotes its activation by the AMPK kinase LKB.
Moreover, Ca2+/calmodulin-dependent kinase kinase beta (CaMKK-beta) has been identified
as being an AMPK kinase. The activity of AMPK is required for autophagy to be induced in
response to starvation in mammalian cells and in yeast in a TORC1-dependent manner.
Moreover, autophagy induction is also dependent on the inhibition of mTORC1 by AMPK
in non-starved cells in response to an increase in free cytosolic Ca2+. In this setting, the acti‐
vation of AMPK and stimulation of autophagy are dependent on CaMKK-beta. The induc‐
tion of autophagy through AMPK activation probably also occurs in other settings, such as
hypoxia. AMPK is probably a general regulator of autophagy upstream of mTOR [16]. An‐
other potential candidate of autophagy regulation down-stream of AMPK is elongation fac‐
tor-2 kinase (eEF-2 kinase), which controls the rate of peptide elongation [17]. Activation of
eEF-2 kinase increases autophagy and slows protein translation. The activity of eEF-2 kinase
is regulated by mTOR, S6K, and AMPK. During periods of ATP depletion, AMPK is activat‐
ed and eEF-2 kinase is phosphorylated, leading to a balance between the inhibition of pep‐
tide elongation and the induction of autophagy. However, how eEF-2 kinase impinges on
the molecular machinery of autophagy remains to be elucidated.
There also is an indirectly-TOR-dependent signaling pathway, named class I PI3K/Akt path‐
way, which when responding to insulin-like and other growth factor signals, the signaling
molecules link receptor tyrosine kinases to activate TOR kinase and thereby repress autoph‐
agy. In addition, autophagy can mediate inactive proteins to degrade to amino acids and
then provide metabolic substrates for cardiac development and ischemic hypoxia forming a
cardiac protection method. Autophagy is among the important mechanisms of hypoxic
adaptation and is perhaps one of the last resorts for the salvage of ATP in hypoxic cells and
organs.
p53 is a responsive stress protein which also plays a crucial role in the regulation of autoph‐
agy through the transcription-dependent/independent pathways. In the transcription-inde‐
pendent pathway, p53 can activate AMPK and down-regulate mTOR; in the transcription-
dependent pathway, through the up-regulation of PTEN (inhibitor of mTOR), the tuberous
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sclerosis-1 (TSC1) gene or cell death gene damage-regulated autophagy modulator 1
(DRAM1), mTOR is down-regulated, and autophagy is induced (Figure 2). In addition, c-jun
N signal kinases (JNK), GTPases, Erk1/2, ceramide are also involved in regulating autopha‐
gy. The cytoplasmic form of p53 has been shown to have an inhibitory effect on autophagy,
suggesting that activation of autophagy by p53 depends on its transactivating effect on
genes such as DRAM1 [18].
Figure 2. Signaling Pathway of Autophagy (Cite from http://www.cellsignal.com/).
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4. The role of autophagy in the maintenance of normal myocardium
In the basal state, autophagy showed low expression in the heart to maintain normal myo‐
cardial function. And most of its function is to perform homeostatic functions by eliminating
long-live organelles and proteins. Autophagy can be upregulated rapidly when myocardi‐
um cells need to generate intracellular nutrients and energy, for example during starvation
or trophic factor withdrawal. Nutritional status, hormonal factors, and other cues like tem‐
perature, oxygen concentrations, and cell density are important in the control of autophagy.
The molecular mechanism of autophagy is still poorly understood. There are more than 30
genes that have been confirmed to be related to autophagy, and half of them are highly con‐
servative in most metazoa [19]. Knockout Atg5 gene (a decisive gene in autophagy) in early
stage adult rat hearts has showed no obvious abnormality, however, after increased after‐
load for one week, left ventricular can cause myocardial ubiquitination and mitochondrial
aggregation, resulting in myocardial hypertrophy and decrease in myocardial contractility,
which indicates that autophagy may play an important role in maintenance of homeostasis,
size of myocardium, general construction and function of myocardial cells. Paradoxically,
partially reduced autophagic activity caused by heterozygous deletion of Beclin 1 improves
cardiac function upon pressure overload. Consistent with this phenomenon, partial suppres‐
sion of autophagy with histone deacetylase (HDAC) inhibitors can ameliorate pressure
overload-induced cardiac hypertrophy in mice [20]. These data suggest that partial, but not
complete, suppression of autophagy may be beneficial.
In short, autophagy adapts to the myocardial energy demand by maintaining energy metab‐
olism, so as to protect the myocardial function.
5. The protective effect of autophagy in myocardial ischemia/hypoxia
In recent years, a large number of studies suggested that autophagy played a protective role
to rescue cardiomyocytes in ischemia/hypoxia. In [21], researchers discovered that 40 mins
of hypoxia induced significant autophagosome and autolysosome formation, according to a
rabbit hypoxic heart model. At the same time, ultrastructural analysis revealed autophago‐
somes in close proximity to swollen and fragmented mitochondria. And in rodents, 30 mins
after ischemia induced dramatic up-regulation of autophagosome formation [22]. Previous
report also demonstrated that the level of autophagy was rapidly increased within 30 mins
after coronary ligation in mice, especially in the risk area (salvaged cardiomyocytes border‐
ing the infarcted area) [23]. Recent work has revealed that inactivation of hypoxia-inducible
factor 1α (HIF-1α) in fibroblasts blunts hypoxia-induced autophagy [24]. These results
strongly suggested that autophagy was activated by myocardial ischemia/hypoxia. Further‐
more, these investigators reported that suppression of autophagy using 3-methyladenine or
bafilomycin A1 enhanced myocyte death triggered by glucose deprivation. During postin‐
farction cardiac remodeling, lysosomes and autophagosomes became more numerous in the
cardiomyocytes, thus ensuring that autophagy could provide enough energy to cardiomyo‐
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cytes. The protective effects of autophagy may be that cells were likely to be provided ener‐
gy, free amino acids and fatty acids through decomposition of their own material.
Additionally, autophagy may maintain cardiomyocyte survival after ischemia/hypoxia by
inhibiting apoptosis [25]. Autophagy is a recycling process of cytoplasmic components, such
as long-lived proteins and organelles. The prosurvival role of autophagy has been observed
in yeast, plants, flies, and mammals. Inhibition of autophagy results in accumulation of cyto‐
plasmic components and promotion of apoptosis. Treatment with pharmacological autopha‐
gy inhibitors and knockdown of Atg genes (Atg5, Atg10, Atg12, and Beclin 1) can increase
apoptosis and cell death in nutrient-deprived cells. In reference [26], autophagy delayed
apoptotic cell death in breast cancer cells following DNA damage. These results suggested
that the effect of inhibiting apoptosis may be related to autophagosomes wrapping damaged
mitochondria, because it will not only prevent the release of cytochrome C, but also inhibit
the formation of apoptotic bodies.
Numerous studies show that mTOR is a key factor in regulating autophagy in ischemia/
hypoxia. In mammalian cells, phosphorylation of mTOR inhibits cell autophagy. Converse‐
ly, dephosphorylation of mTOR enhances autophagy. The activity of mTOR is adjusted by
many factors. AMPK is the important factor which would inhibit the activity of mTOR to
enhance autophagy in ischemia. AMPK serves as a general integrator of metabolic responses
to changes in energy availability and is activated in response to elevations of the AMP/ATP
ratio. Data in reference [27] suggested that autophagy has been reported to be up-regulated
in response to reduced cellular content of ATP. In cultured cardiac myocytes, glucose depri‐
vation caused significant reduction in the levels of ATP, which coincided with up-regulation
of autophagy. Moreover, myocardial ischemia causes a decrease in ATP levels and an in‐
crease in the AMP/ATP ratio, resulting in activation of the AMPK [28]. Under conditions of
stress (including hypoxia and ischemia), a signaling cascade is initiated involving phosphor‐
ylation of AMPK and subsequent inhibition of mTOR. Inhibition of mTOR, in concert with
other protein partners, provides the critical step in initiating autophagosome formation.
6. The expression and regulation of autophagy during myocardial
ischemia/reperfusion
Autophagy is induced during myocardial ischemia. Although it was speculated that activa‐
tion of autophagy may be reverted when ischemia is relieved, in fact, autophagy may be fur‐
ther enhanced by reperfusion [22, 29]. A variety of factors that can regulate the autophagy
during myocardial ischemia/reperfusion, such as ROS generated by mitochondrial respira‐
tion, endoplasmic reticulum stress, calcium, vitamin D compounds, ATP, thapsigargin, cal‐
cium protease, and so on. Different signal transduction pathways are involved in the
occurrence of autophagy at different stages of myocardial ischemia/reperfusion.
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6.1. The role of Beclin 1 in the occurrence of autophagy during myocardial ischemia/
reperfusion
Induction of autophagy in the ischemic phase was accompanied by activation of AMPK and
mTOR. In contrast, autophagy during reperfusion was accompanied by upregulation of Be‐
clin 1 rather than by activation of AMPK. Induction of autophagy and cardiac injury during
the reperfusion phase was significantly attenuated in Beclin 1+/- mice. Collectively, in the is‐
chemic heart, autophagy is stimulated through an AMPK-dependent mechanism, whereas
ischemia/reperfusion stimulates autophagy through a Beclin 1-dependent but not an AMPK-
independent pathway [22]. Using cultured cardiomyocytes, previous studies have demon‐
strated that the inhibition of autophagy by urocortin during the reperfusion phase is
mediated in part by inhibition of Beclin 1 expression, an effect which is mediated by activa‐
tion of the PI3K/Akt pathway [30]. Recent experimental data also show that the clearance of
autophagosomes is impaired in myocardial reperfusion injury which is mediated in part by
ROS-induced decline in LAMP-2A and upregulation of Beclin 1, contributing to increased
cardiomyocyte death [31, 32]. Thus, ROS and ROS-mediated upregulation of Beclin 1 in the
myocardial reperfusion phase may play an important role in the occurrence of autophagy.
Therefore, it is now widely recognized that the autophagy was induced through the AMPK-
eEF2K/mTOR pathway during the ischemic phase of ischemic/reperfusion injury, but was
triggered through the Class III PI3K/Beclin 1 pathway during the reperfusion phase.
6.2. The role of Bcl-2 family members in the occurrence of autophagy during myocardial
ischemia/reperfusion
It is well known that the Bcl-2 family proteins play essential roles in regulating apoptosis in
the cardiovascular system, and several studies have revealed that the Bcl-2 family members
(Bnip3, Bcl-2, Bcl-XL, Bax, etc.) also play important roles in the induction of autophagy dur‐
ing myocardial ischemia/reperfusion injury.
6.2.1. Bnip3
Bnip3 (Bcl-2/adenovirus E1B-19 KD interacting protein 3) with a single Bcl-2 homology 3
(BH3) domain is a pro-apoptotic Bcl-2 family protein which is most sensitive to hypoxia
and plays an important role in myocardial ischemia/reperfusion injury. It was found that
the  overexpression  of  Bnip3  significantly  increased  autophagy,  whereas,  overexpression
of the dominant-negative Bnip3 significantly reduced autophagy induced by myocardial
ischemia/reperfusion  in  HL-1  cardiac  myocytes  [33].  These  results  suggest  that  Bnip3
plays a fundamental role in the induction of autophagy during myocardial ischemia and
reperfusion.  However,  more  studies  are  still  needed  to  clarify  the  role  of  Bnip3  in  re‐
sponse  to  ischemia/reperfusion,  and  the  most  reasonable  explanation  is  that  the  mito‐
chondrial  dysfunction caused by Bnip3 can enhance  the  level  of  autophagy in  order  to
remove damaged organelles.
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6.2.2. Bcl-2/Bcl-XL and Bax
Bcl-2 family members are key modulators of apoptosis that have recently been shown to al‐
so regulate autophagy. Transgenic mice overexpressing the anti-apoptotic human Bcl-2
cDNA in the heart is effective at reducing myocardial reperfusion injury and improving
heart function [34, 35]. However, blockage of the activity of the proapoptotic molecule Bax
in a knockout mouse model attenuates ischemia/reperfusion injury [36]. Recent reports dem‐
onstrated that Beclin 1 possessed a BH3 domain. The BH3 domain of Beclin 1 is bound to
and inhibited by Bcl-2 or Bcl-XL [37, 38]. A BH3 mutant of Beclin1 which has reduced affini‐
ty for Bcl-XL/Bcl-2 was a more potent inducer of autophagy than wild type Beclin 1. Overex‐
pression of Bcl-2 in the heart reduced starvation-induced autophagy. Thus, Bcl-2 not only
functions as an antiapoptotic protein, but also as an antiautophagy protein via its inhibitory
interaction with Beclin 1. These antiapoptosis and antiautophagy functions of Bcl-2 may pro‐
tect the myocardium against ischemia/reperfusion injury [39]. Meanwhile, some studies
found that Bnip3 enhanced autophagy, possibly due to competitive disruption of Bcl-2 bind‐
ing to Beclin 1 [24] or interacting with Rheb to inhibit mTOR [40]. Of course, more studies
are needed to clarify these relationships.
6.3. The role of angiotensin II (Ang II) receptor signaling in the induction of autophagy
during myocardial ischemia/reperfusion
Recent report demonstrated that overexpression of Ang II type 1 (AT1) receptor caused a
significant increase in autophagy after treatment with Ang II in cultured neonatal rat cardio‐
myocytes. However, overexpression of the Ang II type 2 (AT2) receptor can inhibit autopha‐
gy in an Ang II-independent manner. Neonatal cardiomyocytes cultured from hypertrophic
heart rats (HHRs) were more susceptible to AT1 receptor-stimulated autophagy than cardio‐
myocytes from normal heart rats (NHRs). Moreover, there was a greater up-regulation of
autophagic markers in adult HHR hearts than in NHR hearts following ischemia/reperfu‐
sion in vitro [41]. Additionally, AT1 receptor blockaded with olmesartan plays a protective
role in myocardial ischemia-reperfusion injury [42]. Therefore, it is inferred that Ang II/AT1
receptor signaling might also be involved in the stimulation of autophagy during myocar‐
dial ischemia/reperfusion.
Thus, in addition to the Beclin 1, many Bcl-2 family members and angiotensin II/AT1 recep‐
tor signaling may also be involved in the stimulation of autophagy, but additional studies
are needed to clarify the role of these pathways in the occurrence of autophagy during ische‐
mia/reperfusion injury of the heart.
7. The role of autophagy in myocardial ischemia/reperfusion
The autophagy is induced during the ischemia/reperfusion process; however, the role of au‐
tophagy during myocardial ischemia/reperfusion is still inconclusive.
It is well-documented that autophagy occurs at basal levels but can be further induced by
stresses, such as nutrient depletion. Autolysosomal degradation of membrane lipids and
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proteins generate free fatty acids and amino acids, which can be reused to maintain mito‐
chondrial ATP production and protein synthesis and promote cell survival. When the myo‐
cardium was suppressed with ischemia, the blood supply was decreased and the energy
was insufficient, which means that there was an inadequate supply of nutrients. In these
conditions, AMPK acts as a sensor for energy deprivation and activation of AMPK mediates
metabolic adaptation during ischemia.
Many studies have shown that the autophagy induced by lack of blood supply plays a pro‐
tective effect during periods of ischemia. For example, see [43], autophagy is significantly
up-regulated during chronic ischemia in the pig heart. In this model, the level of autophagy
was inversely correlated with that of apoptosis in the ischemic area. The ischemic area was
recovered when the coronary flow was restored, suggesting that autophagy may protect
myocardium from apoptosis during hibernation. Inhibition of endogenous AMPK sup‐
pressed autophagy during prolonged ischemia, which was accompanied by enlargement of
the myocardial infarction. Although one may speculate that activation of autophagy may be
reverted as soon as ischemia is relieved, the level of autophagy in fact further increases dur‐
ing reperfusion. However, a higher level of autophagy is not due to the lack of energy dur‐
ing blood flow restoration after reperfusion. Mechanisms mediating autophagy during
reperfusion appear different from those involved in autophagy during ischemia. Energy cri‐
sis, a major stimulus for autophagy, in the heart is at least partially resolved at the time of
reperfusion [32]. Instead, ROS appears to be a major promoter of autophagy during reperfu‐
sion. ROS induces mitochondrial damage, as evidenced by mitochondrial permeability tran‐
sition pore (mPTP) opening and mitochondrial fragmentation, which in turn promotes
autophagy and/or mitophagy, a specialized form of autophagy which removes mitochon‐
dria [44]. ROS oxidizes and inhibits the cysteine protease activity of Atg4, which results in
LC3 lipidation and autophagy.
Whether autophagy induced during reperfusion is beneficial or detrimental remains con‐
troversial. Previous data [32] have shown that, although autophagic flux is inhibited dur‐
ing ischemia/reperfusion, enhancing autophagic flux during ischemia/reperfusion protects
against  ischemia/reperfusion  injury  in  cardiomyocytes  in  vitro.  The  number  of  Bax  (+)
cardiac  cells  induced by reperfusion was significantly  increased when Beclin-1  or  Atg-5
were knocked out,  but was reduced when there was an overexpression of Beclin-1 [45].
In an in vivo model  of  myocardial  ischemia/reperfusion in pigs,  autophagy was signifi‐
cantly activated when the coronary perfusion is restored, which was accompanied by re‐
duction  of  apoptosis  in  myocardial  cells  and  almost  complete  recovery  of  cardiac
function [46].  Other experiments have also demonstrated that autophagy activation dur‐
ing  myocardial  ischemia/reperfusion  can  remove  the  damaged  mitochondria  caused  by
Bnip3.  These results  indicate  that  autophagy may promote cell  survival  during myocar‐
dial ischemia/reperfusion injury.
In contrast,  study in reference [30] showed that inhibiting autophagy by treatment with
3-methyladenine or by Beclin1 knock down increases the survival  of  cardiomyocytes af‐
ter ischemia/reperfusion in vitro. As results in [22],  the myocardial infarct size increased
by  40%  in  rats  subjected  to  reperfusion,  while  the  infarct  size  was  down-regulated  to
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20% after  the  autophagy gene  Beclin1  knockout.  Inhibition  of  cathepsin,  which  can  de‐
grade  autophagosomes,  can  significantly  reduce  myocardial  cell  damage  and  apoptosis
during the reperfusion phase.  Therefore,  the roles  of  autophagy are not  very clear  dur‐
ing myocardial reperfusion. Further studies are needed to investigate the real roles of au‐
tophagy  in  myocardial  ischemia/reperfusion  injury.  However,  it  is  still  speculated  that
the excessive degradation of important proteins and organelles by autophagy will  cause
cell death.
8. The role of autophagy in aging hearts subjected to ischemia/
reperfusion
Aging is characterized by a progressive accumulation of damaged cells and organs. Autoph‐
agy degraded damaged organelles and macromolecule materials in stress, which prolonged
life span [47]. Autophagy, including the autophagosome formation, the maturation, and the
efficiency of autophagosome-lysosome fusion, as well as the proteolysis activity of lyso‐
somes, declines with age [48]. All of these factors induce an abundance of the lipofuscin pol‐
ymer accumulated in lysosomes. The lipofuscin polymer could not be degraded by
lysosomes. The lysosome with an abundance of lipofuscin polymer lost its bio-function.
Therefore, some damaged organelles and macromolecule materials could not be cleaned up,
which accounted for the aging process. Several studies supported enhancing autophagy as
the most efficient anti-aging intervention [49, 50].
In the heart, autophagy maintains a low basal level to perform biological functions, such as
degrading dysfunctional organelles, maintaining cardiac morphology and function [51, 52].
However, autophagy in cardiomyocytes were up-regulated in response to environmental
stress conditions, such as ATP depletion (e.g. during starvation), oxidative damage, and mi‐
tochondrial permeability transition pore opening (e.g. myocardial ischemia/reperfusion in‐
jury) [53, 54]. Activation of autophagy during ischemia is essential for cell survival and
maintenance of cardiac function. However, autophagy was activated in the heart subjected
to ischemia/reperfusion. Recent reviews show autophagy during reperfusion could be either
protective or detrimental [41]. Serious induction of autophagy accompanied by robust up-
regulation of Beclin-1 could cause autophagic cell death, thereby proving to be detrimental.
If ischemia is mild, activation of autophagy during reperfusion may be modest and thus
may not be harmful.
Until now, there is little information related to autophagy in myocardial ischemia/reperfu‐
sion injury in aging. Our primary data showed that ischemia/reperfusion injury was more
serious in aging hearts compared with young hearts. Beclin-1 was increased in aging hearts
subjected to ischemia/reperfusion, which indicated activated autophagy. However, further
research is needed to know the exact role of autophagy in myocardial ischemia/reperfusion
injury, especially in aging. Moreover, recent studies suggest that autophagy is one of the im‐
portant mechanisms in myocardial ischemia/reperfusion preconditioning. Decreased au‐
tophagy may contribute to the weakened protective role of preconditioning in aging hearts
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subjected to ischemia/reperfusion. Therefore, excessive autophagy results in autophagic cell
death and loss of cardiomyocytes, responsible for the worsening of aging myocardial ische‐
mia/reperfusion injury. The molecular transduction pathways need to be investigated fur‐
ther. It could help to develop therapies that up-regulate the repair qualities of the
autophagic process and down-regulate the cell death aspects, which would be of great value
in the treatment of aging myocardial ischemia/reperfusion injury.
9. The investigative methods of autophagy
9.1. Electron microscopy
Electron microscopy is the most reliable method for testing autophagy at present and can be
used to quantify the autophagic activity of cells. In electron microscopy, the autophagosome
is composed of double membrane structures that wrap abnormal cytoplasmic material.
Then, the autolysosome is composed of the monolayer membrane structure which wraps cy‐
toplasm ingredients at different degradation stages. Because of the difficulty of distinguish‐
ing between autophagosomes and autolysosomes, both of them are often called ‘autophagic
vacuoles’. The proportion of autophagic vacuoles is calcultaed accounting for the total area
or volume of cytoplasm through electron microscopy, which can be used to quantify cell au‐
tophagic activity.
9.2. Specific markers
Atg8 includes three kinds of homology in humans: GABARAP, GATE-16 and LC3. The C-
terminal proteolysis of LC3 is processed by Atg4, based on the residues Phe80 and Leu82 of
LC3 that may be recognized by Atg4, and immediately follows synthesis to yield a soluble
form, LC3-I. LC3-I is converted to a membrane bound form, LC3-II, through a ubiquitin-like
reaction involving Atg7, a ubiquitin-acivating enzyme (E1)-like enzyme, and Atg3, a ubiqui‐
tin-conjugating enzyme (E1)-like enzyme (E2). LC3-II combines to phosphatidyl ethanola‐
mine (PE) on the membrane surface of autophagic vacuoles. In addition, LC3-II is easily
located within the cell after the formation of the fusion protein with the green fluorescent
protein (GFP). Therefore, GFP-LC3 II is usually used as the marker protein of the autopha‐
gosome membrane in mammalian cells.
Beclin 1 is involved in the formation of autophagosomes, which are the mammalian yeast
homologues of Apg6/Vps30. Some researches show that autophagy is significantly attenuat‐
ed in Beclin 1+/- mice, but apoptosis is normal. These results indicate that Beclin 1 is a signif‐
icant positive control gene in autophagy. Therefore, by testing the expression level of
Beclin1, combined with other biochemistry indexes, the autophagic activity of cells can be
monitored and judged dynamically.
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9.3. Monodansylcadaverine (MDC) dyeing
MDC is a kind of fluorescent dye, which is used as a tracer of the autophagic vacuoles. MDC
can specifically bind to the ubiquitin-proteasome sample protein binding systems (Atg8). In
addition, MDC can be absorbed by cells and selectively gathered in autophagic vesicles,
showing punctuate structure under fluorescence microscope. Therefore, the quantitative de‐
tection of autophagy uses this method. However, most of the MDC is not marked in GFP-
LC3. However, MDC is not a reliable marker of autophagosomes. Therefore, other
experimental evidences that represent the autophagic activity of cells are needed.
9.4. Specific agonists and inhibitors
Rapamycin is a novel macrolide immunosuppressant, and induces cell autophagy by inhib‐
iting the mTOR pathway. In scientific studies, Rapamycin is the specific agonist of autopha‐
gy. The main inhibitors of the phosphor-lipin acid radical inositol 3 kinase include 3-MA,
which can specifically block the fusion of autophagic vacuoles and lysosomes. Rapamycin is
widely used as an inhibitor of autophagy, and Wortmannin, LY29400297 and Bafilomycin
A1 are included.
10. Perspectives
Autophagy is intimately involved not only in the physiology of the heart, but also in devel‐
opment of the ischemic heart. The regulation of autophagy may be a new approach for the
treatment of ischemic heart disease. However, to translate the knowledge of autophagy into
treatment of ischemic heart disease, it is necessary to know more precisely about the forma‐
tion, function, mechanism, and regulation of autophagy. When autophagy is protective and
when it is detrimental for the ischemic heart needs further clarification. Another problem is
how to regulate autophagy without affecting other life activities, since even the evolutionar‐
ily conserved autophagy genes also have autophagy-dependent functions. There is continu‐
ing research on this topic. In addition, the signaling mechanisms positively or negatively
regulating autophagy in the heart have not been completely elucidated. Judging from the di‐
versity of autophagy regulators, it is believed that more unknown signal transduction path‐
ways will also be proven to be involved in the activation of autophagy. In short, only
clarifying the activation mechanism, function, time course, and its relationship with cell
death, etc. autophagy can truly benefit patients with ischemic heart disease.
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